IL-1β and IL-17 in cutaneous lupus erythematous skin biopsies: could immunohistochemicals indicate a tendency towards systemic involvement?^☆

Abstract

Background:

Only a fraction of patients with cutaneous lupus erythematosus (CLE) will eventually progress toward systemic disease (SLE).

Objective:

To find inflammatory biomarkers which could predict the progression of cutaneous lupus erythematosus (CLE) into systemic lupus erythematosus (SLE) using immunohistochemical (IHC) assays.

Methods:

Immunohistochemical markers for cytotoxic, inflammatory, and anti-inflammatory responses and morphometric methods were applied to routine paraffin sections of skin biopsies, taken from lesions of 59 patients with discoid lupus, subacute lupus, and lupus tumidus. For the diagnosis of SLE, patients were classified by both the American College of Rheumatology (ACR-82) and the Systemic Lupus International Collaborating Clinics (SLICC-12) systems.

Results:

Skin samples from CLE/SLE +patients presented higher expression of IL-1β (ARC-82: p = 0.024; SLICC-12: p = 0.0143) and a significantly higher number of cells marked with granzyme B and perforin (ARC: p = 0.0097; SLICC-12: p = 0.0148). Biopsies from CLE/SLE- individuals had higher expression of IL-17 (ARC-82: p = 0.0003; SLICC-12: p = 0.0351) and presented a positive correlation between the density of granzyme A+and FoxP3+ cells (ARC-82: p = 0.0257; SLICC-12: p = 0.0285) and CD8+ cells (ARC-82: p = 0.0075; SLICC-12: p = 0.0102), as well as between granulysin-positive and CD8+ cells (ARC-82: p = 0.0024; SLICC-12: p = 0.0116).

Study limitations:

Patients were evaluated at a specific point in their evolution and according to the presence or not of systemic disease. The authors cannot predict how many more, from each group, would have evolved towards SLE in the following years.

Conclusions:

In this cohort, immunohistochemical findings suggested that patients with a tendency to systemic disease will show strong reactivity for IL-1β, while those with purely cutaneous involvement will tend to express IL-17 more intensely.

KEYWORDS
Cutaneous lupus erythematosus; Cytokines; IL-17; Immunohistochemistry; Interleukin-1beta; Systemic lupus erythematosus

Introduction

Among the criteria listed by both the American College of Rheumatology (ACR-82) and the Systemic Lupus International Collaborating Clinics (SLICC-12) for the diagnosis of Systemic lupus erythematosus (SLE), four are related to changes in the skin and mucous membranes.¹,² Cutaneous lupus erythematosus (CLE) is one of the most conspicuous findings, but only a fraction of patients with CLE will eventually develop SLE: among patients with discoid lupus erythematosus (DLE), the most common subtype of CLE, the frequency of progression to SLE ranges from 0% to 28%.³ Characteristics that lead the physician to suspect that this may happen include the number and severity of skin lesions, the titer of antinuclear antibodies, and the presence of systemic symptoms at baseline.⁴ The possibility of progression to SLE causes anxiety in patients with cutaneous lupus. It is important, then, to try to determine which patients are at higher risk of progression to systemic disease.

Previous research has shown the importance of proinflammatory and cytotoxic pathways in lupus erythematosus genesis, usually comparing CLE subtypes. Nevertheless, few studies have focused on differences between CLE/SLE + e and CLE/SLE- patients. Our objective was to find inflammatory biomarkers which could predict the CLE progression into SLE. For this purpose, the authors used Immunohistochemical (IHC) assays in CLE skin biopsies (^{Supplementary Table 1}).

Methods

Skin biopsies from 59 patients with CLE seen at the Dermatology Outpatient Center between 1995 and 2012 were included if: 1) Complete medical records were available, 2) The diagnosis was confirmed by clinical and histological examination, including direct immunofluorescence, when indicated, and 3) Enough remaining paraffin-embedded tissue was found for new sections. These were treated by conventional immunohistochemistry methods, using Polymers (Kit Novolink, Novocastra Laboratories, Newcastle-upon-Tyne, United Kingdom) or the streptavidin-biotin-horseradish peroxidase method (LSAB-HRP, code 0609, Dako Cytomation, Glostrup, Denmark). The lymph node, appendix and tonsil sections were used as controls. Primary antibodies, recovery method and detection system employed are detailed in ^{Supplementary Table 2}.

Biomarkers were used to assess cytotoxic, inflammatory and anti-inflammatory responses. For the analysis of ICAM-1, CD4, CD8, CD25, CD56, Granzyme A, Granzyme B, Gran-ulysin, Perforin and FOXP3, three (x400) fields with the highest density of inflammatory cells and no artifacts were chosen. Their digital images were acquired and analyzed with the aid of the Image J software (Java-based image processing program, Wayne Rasband, NIH, Bethesda, USA, available at http://rsb.info.nih.gov/ij). Both the immunostained cells and the others, present in the same field, were counted. The expression of each marker was then defined as the ratio between the number of immunostained cells and the total number of cells counted. For the IL-6, IL-1β, IL-17, IL-18 and IL-10 markers, the authors used the analysis method described by Popovic et al.⁵

The median age of the 59 patients was 39 years; 55 were female (93.2%); 21 had discoid lupus (DLE), 21 had lupus tumidus (LT) and 17 had subacute lupus (SAL). Nineteen percent of patients with DLE and LT had clinical features of systemic involvement, as classified by both ARC-82 and SLICC-12 criteria. Regarding patients with SAL, 47% were labeled as systemic according to the SLICC-12 classification; in contrast, 70.5% of the same patients were classified as having systemic involvement by the ARC-82 guidelines (Table 1). This difference occurred because SLICC-12 does not include photosensitivity as a criterion, while ARC-82 does not consider synovitis and positive Coombs test criteria.

Table 1
Demographic and clinical data of patients, according to CLE subtypes and the presence of SLE.

CLE subtype	ARC-82		SLICC-12
	SLE+ n (%)	SLE-n (%)	SLE+ n (%)	SLE-n (%)
DLE (n = 21)	4(19)	17 (80.9)	4 (19)	17 (80.9)
Mean age, years	31	45	31	45
Sex, Female (%)	100	82.3	100	82.3
Positive ANA (%)	25	0	25	0
Anti-DNA (%)	75	0	75	0
Positive anti-SM (%)	25	0	25	0
SAL (n = 17)	12 (70.5)	5 (29.4)	8 (47.05)	9 (52.9)
Mean age, years	40	40	39	41
Sex, Female (%)	75	100	75	89
Positive ANA (%)	100	60	100	78
Positive anti-DNA (%)	42	0	51	0
Positive anti-SM (%)	17	0	25	0
LT (n = 21)	4 (19.04)	17 (80.9)	4 (19.04)	17 (80.9)
Mean age, years	40	35	39	35
Sex, Female (%)	100	94	100	94
Positive ANA (%)	100	30	100	30
Positive anti-DNA (%)	25	0	25	0
Positive anti-SM (%)	0	0	0	0

• CLE, Cutaneous Lupus Erythematosus; DLE, Discoid CLE; SAL, Subacute CLE; LT, CLE Tumidus; ARC, American Rheumatology College; SLICC, Systemic Lupus International Collaborating Clinics; SLE, Systemic Lupus Erythematosus.

For statistical analysis, the authors used SAS 9.0^® software. Exploratory data analysis was performed by summary measures (mean, standard deviation, minimum, median, maximum, frequency, and percentage). The groups (SLE + and SLE- patients) were compared by Fisher’s exact test, Chi-Square or Mann-Whitney. The correlation between numerical variables was assessed using Spearman’s coefficient. The adopted level of significance was 5%.

The study was approved by the institution’s ethics committee (# 1214/2010), in which all the Declaration of Helsinki principles were observed.

Results

In all samples, the cells were immunostained by all antibodies (^{Supplementary Table 1}), but for some markers, there were statistically significant differences between CLE/SLE + and CLE/SLE- groups, as detailed in Table 2.

Table 2
Immunohistochemical differences between CLE/SLE + and CLE/SLE- patients, according to ARC-82 and SCLICC classifications.

ARC-82
	CLE/SLE+ (n = 20)	CLE/SLE-(n = 39)	p-value
IL-1β (epidermal cells), n (%)			0.024
1 (mild)	2 (10)	5 (12.8)
2 (moderate)	2 (10)	16 (41)
3 (intense)	16 (80)	18 (46.2)
IL-1β (interstitial)			<0.05
0	0	3
1 (mild)	3	10
2 (moderate)	16	23
3 (intense)	1	3
IL-17 (epidermal cells)			<0.05
1 (mild)	0	5
2 (moderate)	5	8
3 (intense)	15	26
IL-17 (interstitial)			0.0003
1 (mild)	17 (85)	14 (35.9)
2 (moderate to intense)	3 (15)	25 (64.1)
% of CD56 immunostained cells in 3		0.013
fields (mean±SD)	7.2 ± 3.1	5.6 ± 3.9
% of ICAM immunostained cells in 3		0.0095
fields (mean±SD)	47.5 ±6.7	41.8±7.7
SCLICC
	CLE/SLE+ (n = 16)	CLE/SLE-(n = 43)	p-value
Il-1β (epidermal cells)			0.0143
1 (mild)	0 (0)	7 (16.3)
2 (moderate)	2 (12.5)	16 (37.2)
3 (intense)	14 (87.5)	20 (46.5)
IL-1β (interstitial)			<0.05
1 (mild)	2 (12.5)	14 (32.6)
2 (moderate)	13 (81.3)	26 (60.5)
3 (intense)	1 (6.3)	3 (7)
IL-17 (epidermal cells)			<0.05
1 (mild)	0	0
2 (moderate)	14 (87.5)	33 (76.7)
3 (intense)	2 (12.5)	10 (23.3)
IL-17 (interstitial)			0.0351
1 (mild)	12 (75)	19 (44.2)
2 (moderate to intense)	4 (25)	24 (55.8)

• CLE, Cutaneous Lupus Erythematosus; DLE, Discoid CLE; SAL, Subacute CLE; LT, CLE tumidus; ARC, American Rheumatology College; SLICC, Systemic Lupus International Collaborating Clinics; SLE, Systemic Lupus Erythematosus.

In CLE/SLE + patients, as classified by both systems, there was greater expression of IL-1 β (Fig. 1 A and B; ARC-82: p = 0.024; SLICC-12: p = 0.0143), compared to CLE/SLE- patients. Regarding cytotoxic T response markers, CLE/SLE + patients had a significantly higher number of cells marked with Granzyme B and Perforin (Table 3) than CLE/SLE- patients (ARC: p = 0.0097; SLICC-12: p = 0.0148).

Figure 1
Immunohistochemical findings: (A–B) IL-1β. (C–D) IL-17. A–C, SLE patients; B–D, patients with purely cutaneous lupus erythematosus lesions (Original magnification: A = × 100; B-D = × 400).

Table 3
Immunohistochemical differences in Spearman correlation between CLE/SLE + and CLE/SLE- patients, according to ARC-82 and SCLICC classifications.

Variable	CLE/SLE+
	P (ARC-82), n = 20	P (SLICC-12), n = 16
Spearman correlation
Perforin and granzyme B correlation	0.0097	0.0148
	CLE/SLE-
Variable	P (ARC-82), n = 39	P (SLICC-12), n =43
Spearman correlation
FoxP3 and granzyme A correlation	0.0257	0.0285
CD8 and granzyme A correlation	0.0075	0.0102
CD8 and granulysin correlation	0.0024	0.0116

Patients classified by both systems as CLE/SLE- had higher expression of IL-17 (Fig. 1 C and D; ARC-82: p = 0.0003; SLICC-12: p = 0.0351). In addition, there was a positive correlation between the density of Granzyme A + cells, both with that of FoxP3+ (ARC-82: p = 0.0257; SLICC-12: p = 0.0285) and CD8+ cells (ARC-82: p = 0.0075; SLICC-12: p = 0.0102), as well as between Granulysin-positive and CD8+ cells (ARC-82: p = 0.0024; SLICC-12: p = 0.0116). There was also a negative correlation between the density of Granulysin-positive cells and the following SLE criteria (SLICC-12): synovitis (p = 0.0466), hypocomplementemia (p = 0.0408) and anti-SM antibody (p = 0.0252).

Discussion

Macrophages, among other cells, secrete IL-1β through different stimuli, especially IFN-α. The importance of a pro-inflammatory response stimulated by IFN type I, particularly IFN-α, in SLE + patients, is supported by clinical parameters, such as systemic symptoms (such as fever and fatigue), skin biopsies and autopsy findings.⁶,⁷,⁸,⁹ Wenzel et al. showed that patients with disseminated discoid lesions or SAL had increased serum levels of IFN type I, which may indicate an increased risk of developing systemic disease.¹⁰ In the skin, IFN can stimulate the synthesis and overexpression of cytokine receptors that promote the inflow of immune cells and the development of lesions.¹¹ In our sample, this pro-inflammatory response in CLE/SLE + individuals was identified by the expression of IL-1β in skin biopsies. Zhou et al. found increased serum levels of IL-1β in patients with SLE evaluated by cytometric bead array,¹² showing dysregulated T-cell activity.

In contrast, in CLE/SLE- patients, the inflammatory response marker was IL-17. Studies examining the role of IL-17 in lupus erythematosus, to investigate the efficacy of anti-IL-17 immunobiological medications, reported an increase in IL-17 expression in SAL and DLE lesions and in unaffected skin of SLE + patients, compared to healthy controls.⁸,¹³ In our sample, IL-17 expression was significantly higher in CLE/SLE- patients, suggesting that anti-IL-17 drugs could be effective for CLE lesions.

In CLE/SLE + patients with any CLE subtype, the authors identified a cytotoxic T response by increased expression of Granzyme B and Perforin granules, necessary for penetration into target cells. Granzyme B is strongly expressed in healing CLE lesions and significantly increased when compared to SAL and healthy controls.¹⁴ Grassi et al. demonstrated that the expression of Granzyme B + cells was more frequent in skin biopsies from SLE + patients, compared to patients with purely CLE, suggesting that Granzyme B is a key cytotoxicity marker in SLE + individuals.¹⁵ Its role in the genesis of multiple SLE manifestations is also supported by the higher levels of soluble serum Granzyme B in SLE + patients.¹⁶

In CLE/SLE- patients, the positive correlation between CD8+, Granzyme A+, and Granulysin + cell density highlights the importance of cytotoxicity in the pathogenesis of skin lesions. Previous studies have shown a predominance of CD8+ cells in the lesions of patients with DLE, while in other skin subtypes more frequently associated with systemic disease, such as SAL, there is a predominance of CD4+ cells.¹⁷,¹⁸ Other studies emphasized only the role of Granzyme B in CLE lesions, without considering the possible association with systemic disease.¹⁴,¹⁸ Granzyme A associated with IL-17 expression was previously described in psoriatic lesions,¹⁹ which may indicate, in a psoriatic environment, a predominant role in the maintenance of inflammation, rather than cytotoxicity.

The patients in our sample were evaluated at a specific point in their evolution when their symptoms, signs and laboratory results could classify them as CLE/LES- or CLE/LES +patients. The authors cannot predict how many more, from each group, would have evolved toward systemic disease in the next five, or ten years. The authors believe that the probability of developing systemic lupus is greater in the SAL group, and the authors cannot safely exclude the possibility that the differences found may only reflect those between DLE/LT and SAL. It is important to highlight that the authors did not perform comparative analysis between the subgroups of CLE, since our main objective was to evaluate differences between CLE/SLE + and CLE/SLE- patients, regardless of the subtype of CLE.

Conclusion

In this sample, immunohistochemical findings suggest that patients with a tendency to systemic disease will show strong reactivity to IL-1β, while those with purely cutaneous involvement will tend to express IL-17 more intensely. The findings can help, together with clinical data, to identify CLE patients more likely to progress to systemic disease.

Acknowledgments

The statistical analysis was conducted with the help of the biostatistician Cleide Aparecida Moreira Silva, from the Statistics Committee of the Medical Sciences School, UNI-CAMP.

• Financial support
  This work was supported by the São Paulo State Research Support Foundation (FAPESP) – [Process # 11/50037-2 and # 2016/153362].
• ☆
  Study conducted at the Faculty of Medical Sciences, Universidade Estadual de Campinas, Campinas, SP, Brazil.

Appendix A. Supplementary data

Supplementary material related to this article can be found, in the online version, at doi:https://doi.org/10.1016/j.abd.2023.02.007.

References

• ¹
  Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25:1271–7.
• ²
  Petri M, Orbai A-M, Alarcón GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64:2677–86.
• ³
  Chong BF, Song J, Olsen NJ. Determining risk factors for developing systemic lupus erythematosus in patients with discoid lupus erythematosus. Br J Dermatol. 2012;166:29–35.
• ⁴
  Wieczorek IT, Propert KJ, Okawa J, Werth VP. Systemic symptoms in the progression of cutaneous to systemic lupus erythematosus. JAMA Dermatol. 2014;150:291–6.
• ⁵
  Popovic K, Ek M, Espinosa A, Padyukov L, Harris HE, Wahren-Herlenius M, et al. Increased expression of the novel proinflammatory cytokine high mobility group box chromosomal protein 1 in skin lesions of patients with lupus erythematosus. Arthritis Rheum. 2005;52:3639–45.
• ⁶
  Pomara C, Neri M, Bello S, Pennella A, Turillazzi E, Fineschi V. C3a, TNF-alpha and interleukin myocardial expression in a case of fatal sudden cardiac failure during clinic reactivation of systemic lupus erythematosus. Lupus. 2010;19:1246–9.
• ⁷
  Wenzel J, Zahn S, Bieber T, Tüting T. Type I interferon-associated cytotoxic inflammation in cutaneous lupus erythematosus. Arch Dermatol Res. 2009;301:83–6.
• ⁸
  Méndez-Flores S, Hernández-Molina G, Enríquez AB, Faz-Muñoz D, Esquivel Y, Pacheco-Molina C, et al. Cytokines and effector/regulatory cells characterization in the physiopathology of cutaneous lupus erythematous: a cross-sectional study. Mediators Inflamm. 2016;2016:7074829.
• ⁹
  Zhou X, Yan J, Lu Q, Zhou H, Fan L. The pathogenesis of cutaneous lupus erythematosus: The aberrant distribution and function of different cell types in skin lesions. Scand J Immunol. 2021;93:e12933.
• ¹⁰
  Wenzel J, Worenkamper E, Freutel S, Henze S, Haller O, Bieber T, et al. Enhanced type I interferon signaling promotes Th1-biased inflammation in cutaneous lupus erythematosus. J Pathol. 2005;205:435–42.
• ¹¹
  Kirchhof MG, Dutz JP. The immunopathology of cutaneous lupus erythematosus. Rheum Dis Clin North Am. 2014;40:455–74.
• ¹²
  Zhou H, Li B, Li J, Wu T, Jin X, Yuan R, et al. Dysregulated T cell activation and aberrant cytokine expression profile in systemic lupus erythematosus. Mediators Inflamm. 2019;2019:8450947.
• ¹³
  Tanasescu C, Balanescu E, Balanescu P, Olteanu R, Badea C, Grancea C, et al. IL-17 in cutaneous lupus erythematosus. Eur J Intern Med. 2010;21:202–7.
• ¹⁴
  Wenzel J, Uerlich M, Worrenkämper E, Freutel S, Bieber T, Tüting T. Scarring skin lesions of discoid lupus erythematous are characterized by high numbers of skin-homing cytotoxic lymphocytes associated with strong expression of the Type I interferon-induced protein MxA. Br J Dermatol. 2005;153:1011–5.
• ¹⁵
  Grassi M, Capello F, Bertolino L, Seia Z, Pippione M. Identification of granzyme B-expressing CD8-positive T cells in lymphocytic inflammatory infiltrate in cutaneous lupus erythematosus and in dermatomyositis. Clin Exp Dermatol. 2009;34:910–4.
• ¹⁶
  Shah D, Kiran R, Wanchu A, Bhatnagar A. Soluble granzyme B and cytotoxic T lymphocyte activity in the pathogenesis of systemic lupus erythematosus. Cell Immunol. 2011;269:16–21.
• ¹⁷
  Xie Y, Jinnin M, Zhang X, Wakasugi S, Makino T, Inoue Y, et al. Immunohistochemical characterization of the cellular infiltrate in discoid lupus erythematosus. Biosci Trends. 2011;5:83–8.
• ¹⁸
  Wenzel J, Zahn S, Mikus S, Wiechert A, Bieber T, Tüting T, The expression pattern of interferon-inducible proteins reflects the characteristic histological distribution of infiltrating immune cells in different cutaneous lupus erythematosus subsets. Br J Dermatol. 2007;157:752–7.
• ¹⁹
  Cheuk S, Martini E, Bergh K, Chang D, Rethi B, Ståhle M, et al. Granzyme A potentiates chemokine production in IL-17-stimulated keratinocytes. Exp Dermatol. 2017;26:824–7.

Publication Dates

• Publication in this collection
  22 Jan 2024
• Date of issue
  Jan-Feb 2024

History

• Received
  03 Nov 2022
• Accepted
  01 Feb 2023
• Published
  30 Sept 2023